Halagon (halofuginone lactate) – Summary of product characteristics - QP51AX08
Updated on site: 09-Feb-2018
|Nom du médicament:||Halagon|
Contenus de l’article
- 1. NAME OF THE VETERINARY MEDICINAL PRODUCT
- 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
- 3. PHARMACEUTICAL FORM
- 4. CLINICAL PARTICULARS
- 4.1. Target species
- 4.2. Indications for use, specifying the target species
- 4.3. Contraindications
- 4.4. Special warnings
- 4.5. Special precautions for use
- 4.6. Adverse reactions (frequency and seriousness)
- 4.7. Use during pregnancy, lactation or lay
- 4.8. Interaction with other medicinal products and other forms of interaction
- 4.9. Amounts to be administered and administration route
- 4.10. Overdose (symptoms, emergency procedures, antidotes), if necessary
- 4.11. Withdrawal period(s)
- 5. PHARMACOLOGICAL PROPERTIES
- 6. PHARMACEUTICAL PARTICULARS
- 7. MARKETING AUTHORISATION HOLDER
- 8. MARKETING AUTHORISATION NUMBERS
- 9. DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
- 10. DATE OF REVISION OF THE TEXT
1.NAME OF THE VETERINARY MEDICINAL PRODUCT
HALAGON 0.5mg/ml oral solution for calves.
2.QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Halofuginone (as lactate salt)
Equivalent to 0.6086 mg of halofuginone lactate
Benzoic acid (E210)
For the full list of excipients, see section 6.1.
Clear yellow solution.
Cattle (newborn calves).
4.2.Indications for use, specifying the target species
In newborn calves:
•Prevention of diarrhoea due to diagnosed Cryptosporidium parvum infection, in farms with history of cryptosporidiosis.
Administration should start in the first 24 to 48 hours of age.
•Reduction of diarrhoea due to diagnosed Cryptosporidium parvum infection. Administration should start within 24 hours after the onset of diarrhoea.
In both cases, the reduction of oocysts excretion has been demonstrated.
Do not use on an empty stomach.
Do not use in case of diarrhoea established for more than 24 hours and in weak animals. Do not use in case of hypersensitivity to the active substance or to any of the excipients.
4.5.Special precautions for use
Special precautions for use in animals
Administer after colostrum feeding, or after milk or milk replacer feeding only. An appropriate device for oral administration is included. For treatment of anorexic calves, the product should be administered in half a liter of an electrolyte solution. The animals should receive enough colostrum according to good breeding practice.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
People with known hypersensitivity to the active substance or any of the excipients should administer the veterinary medicinal product with caution.
Repetitive contact with the product may lead to skin allergies.
Avoid skin, eye or mucosal contact with the product. Wear protective gloves while handling the product.
In case of skin and eye contact wash the exposed area thoroughly with clean water. If eye irritation persists, seek medical advice.
Wash hands after use.
4.6.Adverse reactions (frequency and seriousness)
- Emdocam - Emdoka bvba
Médicaments délivrés sur ordonnance répertoriés. Fabricant: "Emdoka BVBA"
In very rare cases, an increase in the level of diarrhoea has been observed in treated animals.
The frequency of adverse reactions is defined using the following convention:
-very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
-common (more than 1 but less than 10 animals in 100 animals)
-uncommon (more than 1 but less than 10 animals in 1,000 animals)
-rare (more than 1 but less than 10 animals in 10,000 animals)
-very rare (less than 1 animal in 10,000 animals, including isolated reports).
4.7.Use during pregnancy, lactation or lay
4.8.Interaction with other medicinal products and other forms of interaction
4.9.Amounts to be administered and administration route
For oral use in calves after feeding.
The dosage is: 100 μg of halofuginone / kg bw / once a day for 7 consecutive days, i.e. 4 ml of
HALAGON / 20 kg bw / once a day for 7 consecutive days.
However, in order to make the HALAGON treatment easier, a simplified dosage scheme is proposed:
•35 kg < calves ≤ 45 kg: 8 ml of HALAGON once a day during 7 consecutive days
•45 kg < calves < 60 kg: 12 ml of HALAGON once a day during 7 consecutive days
For smaller or higher weights, a precise calculation should be performed (4 ml/20 kg).
To ensure a correct dosage, an appropriate metering pump for administration of ‘HALAGON’ is included.
1)Screw the metering pump on the bottle.
2)Remove the protector cap from the nozzle.
3)If the metering pump is used for the first time (or hasn’t been used for a few days), carefully pump till a drop of solution is formed on top of the nozzle.
4)Restrain the calf and insert the nozzle of the metering pump into the calves mouth.
5)Pull the trigger of the metering pump completely for release of a dose that equals 4 ml of solution. Pull twice or three times, respectively, for administration of the desired volume (8 ml for calves of 35 – 45 kg and 12 ml for calves of 45 – 60 kg, respectively).
6)Put the protector cap back on the nozzle.
The consecutive treatment should be done at the same time each day.
Once the first calf has been treated, all the forthcoming
4.10. Overdose (symptoms, emergency procedures, antidotes), if necessary
As symptoms of toxicity may occur at twice the therapeutic dose, it is necessary to apply the recommended dosage strictly. Symptoms of toxicity include diarrhoea, visible blood in faeces, decline in milk consumption, dehydration, apathy and prostration. Should clinical signs of overdosing occur, the treatment must be stopped immediately and the animal fed unmedicated milk or milk replacer. Rehydration may be necessary.
4.11. Withdrawal period(s)
Meat and offal: 13 days.
Pharmacotherapeutic group: Other antiprotozoal agents, halofuginone.
- Halocur - QP51AX08
Médicaments délivrés sur ordonnance répertoriés. Code ATC: "QP51AX08"
ATCvet code: QP51AX08.
The active substance, halofuginone, is an antiprotozoal agent of the quinazolinone derivatives group (nitrogenous polyheterocycles). Halofuginone lactate is a salt whose antiprotozoal properties and efficacy against Cryptosporidium parvum have been demonstrated both in in vitro conditions and in artificial and natural infections. The compound has a cryptosporidiostatic effect on Cryptosporidium parvum. It is mainly active on the free stages of the parasite (sporozoïte, merozoïte). The concentrations to inhibit 50% and 90% of the parasites, in an in vitro test system, are IC50 < 0.1 μg/ml and IC90 of 4.5 μg/ml, respectively.
The bioavailability of the drug in the calf following single oral administration is about 80%. The time necessary to obtain the maximum concentration Tmax is 11 hours. The maximum concentration in plasma Cmax is 4 ng/ml. The apparent volume of distribution is 10 l/kg. The plasmatic concentrations of halofuginone after repeated oral administrations are comparable to the pharmacokinetic pattern after single oral treatment. Unchanged halofuginone is the major component in the tissues. Highest values have been found in the liver and the kidney. The product is mainly excreted in the urine. The terminal elimination
6.1.List of excipients
Benzoic acid (E210)
Lactic acid (E270)
6.4.Special precautions for storage
Keep the bottle in the outer carton in order to protect from light.
6.5.Nature and composition of immediate packaging
Cardboard box containing one bottle
6.6.Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.
The product should not enter watercourses as this may be dangerous for fish and other aquatic organisms.
7.MARKETING AUTHORISATION HOLDER
J. Lijsenstraat 16
8.MARKETING AUTHORISATION NUMBERS
9.DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION
Date of first authorisation: 13 December 2016
10.DATE OF REVISION OF THE TEXT
Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu/.
PROHIBITION OF SALE, SUPPLY AND/OR USE